melphalan pharmexon 50 mg powder and solvent for solution for injection/infusion
pharmexon consulting s.r.o - melphalan hydrocholoride - powder and solvent for solution for injection/infusion - 50 milligram(s) - nitrogen mustard analogues; melphalan
sofentil 50mcg/ml solution for injection or infusion
medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - sufentanil - solution for injection/infusion - sufentanil 50 µg/ml - anesthetics
melphalan tillomed 50 mg powder and solvent for solution for injection/infusion
tillomed pharma gmbh - melphalan hydrochloride - powder and solvent for solution for injection/infusion - 50 milligram(s) - nitrogen mustard analogues; melphalan
normosol-m and dextrose- dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate injection, solution
icu medical inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium acetate (unii: m911911u02) (potassium cation - unii:295o53k152), magnesium acetate (unii: 0e95jzy48k) (magnesium cation - unii:t6v3lhy838) - normosol-m and 5% dextrose injection (multiple electrolytes and 5% dextrose injection type 1, usp) is indicated for parenteral maintenance of routine daily fluid and electrolyte requirements with minimal carbohydrate calories from dextrose. magnesium in the formula may help to prevent iatrogenic magnesium deficiency in patients receiving prolonged parenteral therapy. none known.
melphalan medac 50 mg powder and solvent for solution for injection/infusion
medac gesellschaft für klinische spezialpräparate mbh - melphalan - powder and solvent for solution for injection/infusion - 50 milligram(s) - melphalan
bortezomib ever pharma bortezomib 3.5 mg/1.4 ml solution for injection vial
interpharma pty ltd - bortezomib, quantity: 3.5 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; mannitol - bortezomib ever pharma, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib ever pharma, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib ever pharma is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib ever pharma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
bortezomib ever pharma bortezomib 2.5 mg/1 ml solution for injection vial
interpharma pty ltd - bortezomib, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; mannitol - bortezomib ever pharma, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib ever pharma, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib ever pharma is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib ever pharma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
bortezomib accord bortezomib 3.5 mg/1.4 ml solution for injection vial
accord healthcare pty ltd - bortezomib, quantity: 3.5 mg - injection, solution - excipient ingredients: mannitol; water for injections - bortezomib accord, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib accord, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib accord is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
bortezomib accord bortezomib 2.5 mg/1 ml solution for injection vial
accord healthcare pty ltd - bortezomib, quantity: 2.5 mg - injection, solution - excipient ingredients: mannitol; water for injections - bortezomib accord, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib accord, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib accord is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
ringer’s solution for infusion, viaflo container
baxter holding b.v. - sodium chloride; potassium chloride; calcium chloride dihydrate - solution for infusion - 0 milligram(s)/litre - solutions affecting the electrolyte balance; electrolytes